Back to top
more

The Cooper Companies (COO)

(Real Time Quote from BATS)

$102.14 USD

102.14
637,983

+0.14 (0.14%)

Updated Nov 13, 2024 01:34 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -51.92% and 65.81%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Henry Schein (HSIC) Q1 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Henry Schein (HSIC) delivered earnings and revenue surprises of -2.42% and 1.13%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

XRAY vs. COO: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

XRAY vs. COO: Which Stock Is the Better Value Option?

Cardinal Health (CAH) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Cardinal (CAH) delivered earnings and revenue surprises of 17.57% and 1.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Industry Outlook Highlights West Pharmaceutical Services, The Cooper Companies and Henry Schein

by Zacks Equity Research

West Pharmaceutical Services, The Cooper Companies and Henry Schein have been highlighted in this Industry Outlook article.

3 Dental Supplies Stocks to Buy as Industry Prospects Recover

by Zacks Equity Research

Here, we discuss three stocks from the Dental Supplies industry that are likely to create wealth for investors. These include WST, COO and HSIC.

Here's Why You Should Retain NextGen (NXGN) Stock for Now

by Zacks Equity Research

NextGen's (NXGN) strong product portfolio and continued demand for its solutions raise optimism about the stock.

Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio

by Zacks Equity Research

AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Catalent (CTLT) Declines on Profit Warnings and CFO Exit

by Zacks Equity Research

Catalent (CTLT) issues a profit warning for third-quarter fiscal 2023 amid supply chain disruptions and operational challenges. It also announces the departure of its CFO.

Reasons to Retain Cardinal Health (CAH) in Your Portfolio

by Zacks Equity Research

Cardinal Health (CAH) continues to gain traction from solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.

3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about DexCom (DXCM) owing to its strong product portfolio.

Here's Why You Should Retain Catalent (CTLT) Stock for Now

by Zacks Equity Research

Catalent's (CTLT) product and service launches, and a slew of strategic deals raise optimism about the stock.

Here's Why You Should Add Stryker (SYK) Stock to Your Portfolio

by Zacks Equity Research

Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio. However, pricing pressure weighs on the company.

Here's Why You Should Retain Surmodics (SRDX) Stock for Now

by Zacks Equity Research

Investors continue to feel optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.

Here's Why You Should Retain Inari Medical (NARI) Stock Now

by Zacks Equity Research

Inari Medical (NARI) continues to benefit from its commitment to understand the venous system. However, its dependency on the adoption of products is concerning.

Here's Why You Should Retain CONMED (CNMD) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about CONMED (CNMD), owing to its broad product spectrum.

Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio

by Zacks Equity Research

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

XRAY or COO: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

XRAY vs. COO: Which Stock Is the Better Value Option?

Reasons to Add The Cooper Companies (COO) to Your Portfolio

by Zacks Equity Research

The Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to drive the top line further.

Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Stock Now

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.

Dexcom (DXCM) Launches G6 Glucose Monitoring System in Canada

by Zacks Equity Research

Dexcom (DXCM) announces the availability of standard of care in diabetes management - G6 CGM system - for type 1 and 2 patients with basal and bolus insulin or using an insulin pump in Canada.

Here's Why You Should Retain PerkinElmer (PKI) Stock Now

by Zacks Equity Research

PerkinElmer (PKI) continues to gain from a solid product portfolio despite forex woes.

Reasons to Retain West Pharmaceutical (WST) in Your Portfolio

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.

Here's Why You Should Retain Patterson Companies (PDCO) Stock

by Zacks Equity Research

Investors are optimistic about Patterson Companies' (PDCO) strong product line.

Catalent (CTLT) Inks Deal for New & Effective Drug Delivery

by Zacks Equity Research

Catalent (CTLT) will use Bhami Research Laboratory's technology to evaluate and develop drug-delivery system for high-concentration therapies, thereby increasing effectiveness.